Tag: Established molecules
-
Optimisation of a Portfolio of Established Brands
by
Challenge: The problem with portfolios is that they are looked at as one and this does not reflect the reality. This portfolio was 15 medicines, the majority of which were in one therapy area. As a whole the portfolio was losing volumes year on year, losing revenue and losing margin to an even greater degree…
-
Category H introduction …. the end of branded generics in the UK?
by
Category H introduction has been announced although detail is lacking. It will undoubtedly affect branded generics and this article gives an outline as to how and why.
-
Repurposed molecule > Go-to-market & launch strategy > Operational structure options
by
Challenge: This Germany headquartered developer wanted to enter the UK market with a repurposed molecule (new form, new indication). They needed confirmation of the likely pricing window and volume forecast. They wanted advice on go-to-market and launch strategy and also the operational structure options to succeed in this less familiar, non-EU market.
-
Established molecules – more than “just” generics?
by
A frequent response to hearing the words “established molecules” is “so you mean generics, right?” Well yes, and no! There is more to it than “just generics” and in fact this is an exciting and profitable area of pharma and one we love to work on here at Hawk Pharma Consulting.
